Tissue Microarray Applications in Drug Discovery for Pancreatic Cancer
The rising incidence of pancreatic cancer combined with limited responses to chemotherapy highlights the need for improved molecular characterization in this highly lethal cancer. The discovery and validation of novel biomarkers are urgently needed to improve early detection and thereby improve survival outcomes. The introduction and widespread application of tissue microarrays (TMAs) over the past decade provide a valuable tool for validation of abundance and cellular localization of expressed proteins and RNA transcript levels contextually within the complex tissue morphology of pancreatic cancer. The TMA format offers a standardized platform to optimize and validate newly identified biomarkers and drug targets in pancreatic cancer research to patient tumor samples to provide critical links in advancing cancer research findings to the clinical setting.
KeywordsPancreatic Cancer Tissue Core FFPE Tissue Formalin Fixation National Human Genome Research Institute
- Fejzo MS, Slamon DJ (2001) Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol 159:1645–1650Google Scholar
- Hardisson D, Moreno-Bueno G, Sanchez L et al (2003) Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability.Mod Pathol 16:1148–1158CrossRefPubMedGoogle Scholar
- Kononen J, Hostetter G, Sauter G et al (2002) Construction of tissue microarrays. David Bowtell and Joe Sambrook (Eds.) In: DNA Microarrays: A Molecular Cloning Manual, Cold Spring Harbor Laboratory Press, New YorkGoogle Scholar